SARS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4313369	1.00	3/20
SCHEMBL21067959	1.00	3/20
SCHEMBL13773429	0.84	3/20
SCHEMBL29580149	0.84	3/20
SCHEMBL10069778	0.63	3/20
SCHEMBL12714797	0.36	3/20
SCHEMBL116374	0.60	2/20
SCHEMBL117518	0.60	2/20
SCHEMBL117520	0.59	2/20
SCHEMBL18630526	0.58	2/20
SCHEMBL10619733	0.56	2/20
SCHEMBL14201600	0.56	2/20
SCHEMBL24981044	0.48	2/20
SCHEMBL24981053	0.48	2/20
SCHEMBL11426071	0.48	2/20
SCHEMBL3187637	0.87	1/20
SCHEMBL3187665	0.87	1/20
SCHEMBL21068060	0.87	1/20
SCHEMBL178823	0.85	1/20
SCHEMBL178824	0.85	1/20

Clinical trials — most relevant to SARS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection	PHASE3	COMPLETED
Ivermectin and Nitazoxanide Combination Therapy for COVID-19	PHASE2/PHASE3	UNKNOWN
Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH	PHASE3	UNKNOWN
Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC	PHASE3	UNKNOWN
Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia	PHASE2/PHASE3	UNKNOWN
Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial	PHASE3	UNKNOWN
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19	PHASE3	SUSPENDED
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19	PHASE3	COMPLETED
Efficacy of Adaptogens in Patients With Long COVID-19	PHASE2/PHASE3	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Favipiravir vs Hydroxychloroquine vs Control in COVID -19	PHASE2	COMPLETED
Impact of Colchicine and Low-dose Naltrexone on COVID-19	PHASE2	COMPLETED
HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19	PHASE2	WITHDRAWN
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Angiotensin 1-7 as a Therapy in the Treatment of COVID-19	PHASE2	UNKNOWN
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease	PHASE2	UNKNOWN
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors	nan	ACTIVE_NOT_RECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients	nan	COMPLETED
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2	nan	COMPLETED
Immunological Profiling of Patients With COVID-19 in Respiratory Distress	nan	COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19	nan	COMPLETED
Crowdsourcing an Open COVID-19 Imaging Repository for AI Research	nan	COMPLETED
Prospective Two-arm Study of Fertility in Men With COVID-19	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SARS1 binder may also engage these)

Protein	Name	Similarity
Q5R9K9	—	1.000	Q5R9K9 →
Q6P799	—	1.000	Q6P799 →
Q4R4U9	—	1.000	Q4R4U9 →
P13642	—	1.000	P13642 →
Q6DRC0	—	1.000	Q6DRC0 →
Q9GMB8	—	1.000	Q9GMB8 →
P26638	—	1.000	P26638 →
P26636	—	1.000	P26636 →
Q18678	—	0.998	Q18678 →
Q8RWT8	—	0.996	Q8RWT8 →
Q9UTB2	—	0.996	Q9UTB2 →
Q9SSK1	—	0.993	Q9SSK1 →
A5HXR1	—	0.992	A5HXR1 →
Q9ZPI1	—	0.992	Q9ZPI1 →
Q9Y7Y8	—	0.992	Q9Y7Y8 →
Q87QP1	—	0.992	Q87QP1 →
P38708	—	0.992	P38708 →
Q92GA7	—	0.992	Q92GA7 →
Q7SYV0	—	0.992	Q7SYV0 →
C3LIY9	—	0.992	C3LIY9 →
A0AM81	—	0.992	A0AM81 →
Q41437	—	0.992	Q41437 →
Q0W8S5	—	0.991	Q0W8S5 →
Q1RKF4	—	0.991	Q1RKF4 →
A9A4V3	—	0.991	A9A4V3 →
Q041F5	—	0.991	Q041F5 →
Q63HF6	—	0.991	Q63HF6 →
A8GPX3	—	0.991	A8GPX3 →
P34647	—	0.991	P34647 →
Q5GSH2	—	0.991	Q5GSH2 →